- Home
- ORMP vs GALT Comparison
ORMP vs GALT Comparison
Compare ORMP & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORMP
- GALT
- Stock Information
- Founded
- ORMP 2002
- GALT 2000
- Country
- ORMP United States
- GALT United States
- Employees
- ORMP N/A
- GALT N/A
- Industry
- ORMP Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- ORMP Health Care
- GALT Health Care
- Exchange
- ORMP Nasdaq
- GALT Nasdaq
- Market Cap
- ORMP 104.6M
- GALT 232.3M
- IPO Year
- ORMP N/A
- GALT N/A
- Fundamental
- Price
- ORMP $2.41
- GALT $5.25
- Analyst Decision
- ORMP
- GALT Strong Buy
- Analyst Count
- ORMP 0
- GALT 3
- Target Price
- ORMP N/A
- GALT $6.00
- AVG Volume (30 Days)
- ORMP 135.1K
- GALT 259.7K
- Earning Date
- ORMP 11-07-2025
- GALT 11-12-2025
- Dividend Yield
- ORMP N/A
- GALT N/A
- EPS Growth
- ORMP N/A
- GALT N/A
- EPS
- ORMP N/A
- GALT N/A
- Revenue
- ORMP $2,000,000.00
- GALT N/A
- Revenue This Year
- ORMP N/A
- GALT N/A
- Revenue Next Year
- ORMP N/A
- GALT N/A
- P/E Ratio
- ORMP N/A
- GALT N/A
- Revenue Growth
- ORMP N/A
- GALT N/A
- 52 Week Low
- ORMP $1.82
- GALT $0.73
- 52 Week High
- ORMP $3.09
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- ORMP 53.15
- GALT 60.98
- Support Level
- ORMP $2.23
- GALT $4.77
- Resistance Level
- ORMP $2.45
- GALT $5.35
- Average True Range (ATR)
- ORMP 0.12
- GALT 0.28
- MACD
- ORMP -0.01
- GALT 0.01
- Stochastic Oscillator
- ORMP 64.52
- GALT 81.36
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.